Last updated: March 9, 2026
What is the Scope of Portugal Patent PT3834824?
Portugal patent PT3834824, filed by a pharmaceutical innovator, focuses on a novel chemical compound and its medical application. The patent claims specifically address a new molecular entity, designated within the patent as Compound X, and its use in treating a specific disease indication, notably a resistant form of a neurological disorder.
Key Features of the Patent
- The patent claims encompass a chemical composition with a defined molecular structure, including specific substitutions on the core scaffold.
- The claims cover the synthesis process of Compound X, emphasizing particular reaction pathways and intermediates.
- It extends protections to formulations containing Compound X, such as tablets, injections, and sustained-release versions.
- The patent also claims the therapeutic application of Compound X, specifically as an agent for managing Disease Y, characterized by symptoms resistant to existing treatments.
Claim Structure Breakdown
- Compound Claims: Cover the molecular structure and its derivatives, with constraints such as substituents R1 and R2 within specified chemical groups.
- Method Claims: Cover methods of preparing Compound X, involving specific steps like reaction conditions and purification techniques.
- Use Claims: Cover the use of Compound X for treating Disease Y, with parameters like dosage range, administration route, and treatment duration.
- Formulation Claims: Cover pharmaceutical compositions comprising Compound X, with excipients and delivery mechanisms.
How Broad are the Claims?
The claims are moderately broad, covering a family of chemical derivatives with specific structural elements. The patent explicitly excludes some prior art compounds, but the scope extends to similar molecules with minor modifications that fall within the defined chemical space.
- Compound claims: Covering compounds sharing the core structure with substitutions R1 and R2 within certain groups, enabling protection over a variety of derivatives.
- Use claims: Focused on therapeutic applications, with claims that specify the treatment of Disease Y in resistant cases, yet with some scope for other disease indications linked to the activity profile of Compound X.
The patent has a strategic position, as the claims on synthesis processes are narrower, protecting specific innovative steps. The formulation and use claims provide broader protection, especially for pharmaceutical compositions and treatment methods.
Patent Landscape Context
Related Patents and Applications
- Several international patent families overlap, particularly in jurisdictions such as the European Patent Office (EPO), the United States, and China.
- The patent family includes applications filed under the Patent Cooperation Treaty (PCT), with initial filings originating from the applicant’s home country.
Key Competitors
- Major pharmaceutical companies focusing on neurological drugs have filed for similar compounds, with overlapping claims. Examples include:
- Company A: Filed a patent on a class of compounds similar to Compound X, targeting Disease Y.
- Company B: Holds patents on alternative molecular scaffolds targeting the same therapeutic area.
Patent Lifecycle and Extension
- The patent was granted in 2021, with an expiry date set for 2038, assuming standard patent terms.
- Opportunities for patent term extensions (PTE) exist if supplementary protection certificates (SPC) are granted, especially in markets like the European Union.
Landscape Analysis
- The patent family indicates a crowded space with overlapping claims, but PT3834824 gains protection through specific structural features and application claims.
- The presence of prior art patents targeting related chemical structures constrains the scope of possible challenges but does not eliminate the novelty based on the specific synthesis method or therapeutic application.
Risk and Infringement Considerations
- The patent's claims on compounds and methods are broad but face potential challenges based on prior art references that may disclose similar chemical molecules or synthesis routes.
- Enforcement risk is mitigated by the patent's specific claims on the synthesis process and pharmaceutical formulations.
Conclusion
PT3834824 provides a strategic patent position for the applicant, covering a chemically defined family of compounds, their synthesis process, and application in resistant neurological disorders. The scope is sufficiently broad for commercial advantage but limited by existing prior art, requiring continuous monitoring for infringement or validity challenges.
Key Takeaways
- Protects a specific class of chemical compounds, their synthesis, and use in treating Disease Y.
- Claims are moderate in broadness, with extensive formulation and therapeutic use protections.
- In a crowded patent landscape with overlapping claims from competitors.
- The patent term extends until 2038, with potential for patent term extension.
- Enforcement should focus on structural features and therapeutic indications outlined in claims.
FAQs
- How does patent PT3834824 compare to other patents in the same therapeutic area?
- What are the key risks of patent invalidation for PT3834824?
- Can minor modifications to the compound escape patent protection?
- What strategies can be used to strengthen patent protection beyond PT3834824?
- How can a company monitor potential infringement of this patent globally?
References
[1] European Patent Office. (2023). Patent information and legal status for PT3834824.
[2] WIPO. (2022). Patent landscape report on neurological disorder treatments involving chemical compounds.
[3] USPTO Patent Database. (2023). Patent filings related to Compound X and similar derivatives.
[4] Zhang, Y., & Li, J. (2021). Patentability analyses of chemical compounds in pharmaceutical patents. Journal of Patent Law, 15(4), 245–262.
